CareDx (CDNA) Misses Q2 EPS by 9c, Maintains FY Rev. Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
CareDx, Inc. Reports Second Quarter 2015 Financial Results
August 10, 2015 4:01 PM EDTBRISBANE, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the second quarter ended June 30, 2015.
Recent highlights:
Record volume of more than 3,250 AlloMap diagnostic tests administered and processed, with a continued reimbursement of rate of 80%. Total revenues for the second quarter of $7.1 million, a year-over-year increase of 5%. DART 1, a multi-center kidney transplant study using cfDNA, was initiated, and six leading medical... More